Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genscript Biotech Corp
(OP:
GNNSF
)
1.605
UNCHANGED
Last Price
Updated: 1:34 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genscript Biotech Corp
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
August 01, 2024
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...
Via
Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
July 20, 2024
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Via
Talk Markets
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
3 DNA Stocks to Buy for the Synthetic Biology Revolution
May 14, 2023
Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche.
Via
InvestorPlace
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
February 17, 2023
Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023.
Via
InvestorPlace
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
January 21, 2023
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in...
Via
Talk Markets
Three Pharma Stocks to Sell Before They Die
December 24, 2022
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January.
Via
InvestorPlace
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
December 10, 2022
In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and...
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.